

# HUNTINGTON'S DISEASE NN105 STAIR



SRX246: Safety, Tolerability, and Activity in Irritable Subjects with HD (STAIR)

## WHAT IS THE PURPOSE OF THE STUDY?

To learn if a new investigational drug, SRX246, is a safe and effective drug for people with Huntington's Disease (HD) who have symptoms of irritability or aggression. We will compare the study drug SRX246 to a placebo. Participants will have a 2 out of 3 chance of receiving the study drug (SRX246) and 1 out of 3 chance of receiving placebo.

## AM I ELIGIBLE?

- ⇒ Must be at least 18 years old and have sufficient English skills for the questionnaires.
- ⇒ Must have a diagnosis of HD and experience symptoms of irritability or aggression.
- ⇒ You must have a study partner who is willing to participate in the study.

*The study coordinator will provide you with a full list of requirements for participation.*

## STUDY VISITS

Study visits will include 1 screening visit, 1 baseline visit, 5 clinic visits and 2 telephone visits. If you participate in the study, you will be paid \$50 and your study partner \$30 for every clinic visit completed to assist with meals, travel and parking.

## WHAT ARE THE BENEFITS OF THE STUDY?

You may or may not benefit from taking part in this research study.



The NEXT Generation of Neurologic Treatments  
NIH-Network for Excellence in Neuroscience Clinical Trials

For additional information, visit [ClinicalTrials.gov](https://ClinicalTrials.gov), identifier number NCT02507284